Division of Gastroenterology and Hepatology, Department of Medicine, McGill University Health Center, Montreal, Canada.
Department of Pathology, McGill University Health Center, Montreal, Canada.
Am J Gastroenterol. 2022 Oct 1;117(10):1632-1638. doi: 10.14309/ajg.0000000000001912. Epub 2022 Jul 21.
Endoscopic healing is currently considered the main target in the management of ulcerative colitis (UC). There are conflicting data about the role of histology as a stricter treatment objective. We aim at evaluating the additional benefit of histologic remission over endoscopic remission.
We performed a prospective observational study at the McGill University Health Center. We enrolled adult patients with UC in clinical remission for at least 3 months undergoing a colonoscopy. Endoscopic disease activity was based on the Mayo endoscopic score. Rectal biopsies were obtained, and the histologic activity was evaluated using the Geboes score (active disease defined as Geboes score ≥ 3.1) with the addition of assessing the presence of basal plasmacytosis. Patients were followed up for 12 months for disease relapse defined as a partial Mayo score of > 2. At the time of relapse or end of follow-up, all patients underwent repeat endoscopic evaluation. The primary end point was clinical relapse.
Two hundred fifty-three patients were included. The presence of basal plasmacytosis was associated with relapse (adjusted odd ratio = 2.07, 95% confidence interval [CI] 1.06-4.18, P = 0.042). Time to clinical relapse was significantly higher for patients with Mayo endoscopic score > 0 with adjusted hazard ratio = 2.65, 95% CI 1.31-5.39, and P = 0.007. Time to clinical relapse was not significantly higher for Geboes score ≥ 3.1 with adjusted hazard ratio = 1.29, 95% CI 0.67-2.49, and P = 0.45.
Active histologic disease did not affect time to clinical relapse in patients with UC who achieved endoscopic remission while the presence of basal plasmacytosis is associated with relapse.
内镜愈合目前被认为是溃疡性结肠炎(UC)治疗的主要目标。组织学作为更严格的治疗目标的作用存在相互矛盾的数据。我们旨在评估组织学缓解相对于内镜缓解的额外益处。
我们在麦吉尔大学健康中心进行了一项前瞻性观察性研究。我们招募了至少 3 个月处于临床缓解期并接受结肠镜检查的成年 UC 患者。内镜疾病活动度基于 Mayo 内镜评分。获取直肠活检标本,使用 Geboes 评分(活跃期定义为 Geboes 评分≥3.1)评估组织学活动度,并评估基底浆细胞的存在。患者在 12 个月内进行随访,以评估部分 Mayo 评分>2 的疾病复发。在复发或随访结束时,所有患者均接受重复内镜评估。主要终点是临床复发。
共纳入 253 例患者。基底浆细胞的存在与复发相关(调整后的优势比=2.07,95%置信区间[CI]1.06-4.18,P=0.042)。Mayo 内镜评分>0 的患者临床复发时间明显更长,调整后的危险比=2.65,95%CI 1.31-5.39,P=0.007。Geboes 评分≥3.1 的患者临床复发时间无显著延长,调整后的危险比=1.29,95%CI 0.67-2.49,P=0.45。
在达到内镜缓解的 UC 患者中,活跃的组织学疾病不会影响临床复发时间,而基底浆细胞的存在与复发相关。